# Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals

> **NCT04207840** · PHASE4 · COMPLETED · sponsor: **Amphastar Pharmaceuticals, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Pharmacokinetics
- Epinephrine
- Albuterol
- Asthma
- Anaphylaxis

## Interventions

- **COMBINATION_PRODUCT:** Epinephrine (0.125 mg/inhalation)
- **COMBINATION_PRODUCT:** Epinephrine Injection Auto-Injector (0.3mg/0.3mL)
- **COMBINATION_PRODUCT:** Albuterol Sulfate (0.09 mg/inhalation)

## Key facts

- **NCT ID:** NCT04207840
- **Lead sponsor:** Amphastar Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-09
- **Primary completion:** 2019-12-20
- **Final completion:** 2019-12-23
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04207840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04207840, "Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04207840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*